Coskun 2022 mmc3 Table 3 + mmc1 Table S8 Phase 1 single-ascending-dose study (NCT03841630, n=45, conducted in Singapore)
A 2022 dose-response RCT (Yi et al., Geroscience) at 300/600/900 mg/day raised NAD+ dose-dependently with no safety issues at 60 days
67,68,69 Recently, a P495T variant of the GHR that is associated with increased incidence of lung cancer in various ethnic groups was shown to prolong GH signaling, which leads to increased expression of genes associated with tumor proliferation and epithelial-to-mesenchymal transition
Sunscreen is the most significant step you can take to stop your skin from producing too much melanin
Together, BPC-157 and TB-500 work synergistically increasing blood flow to injury sites, aggregating and activating repair cells, and reducing inflammation and scarring